---
title: "Key facts: Arrowhead, Novartis finalize global collaboration; Swiss firms safe from U.S. drug tariffs"
description: "Arrowhead Pharmaceuticals has finalized a global license and collaboration agreement with Novartis, marking a significant partnership in the pharmaceutical sector.1Novartis and other Swiss pharma firm"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262146326.md"
published_at: "2025-10-22T02:03:10.000Z"
---

# Key facts: Arrowhead, Novartis finalize global collaboration; Swiss firms safe from U.S. drug tariffs

> Arrowhead Pharmaceuticals has finalized a global license and collaboration agreement with Novartis, marking a significant partnership in the pharmaceutical sector.1Novartis and other Swiss pharma firms expect no impact from the 100% tariff on branded drug imports by the U.S., as they continue their expansion in the market.2

-   Arrowhead Pharmaceuticals has finalized a global license and collaboration agreement with Novartis, marking a significant partnership in the pharmaceutical sector.1
-   Novartis and other Swiss pharma firms expect no impact from the 100% tariff on branded drug imports by the U.S., as they continue their expansion in the market.2

### Related Stocks

- [NVS.US - NOVARTIS AG](https://longbridge.com/en/quote/NVS.US.md)
- [ARWR.US - ArrowHead Pharma](https://longbridge.com/en/quote/ARWR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| -Novartis to exit Indian unit in $159 million deal | Swiss drugmaker Novartis is selling its 70.68% stake in its Indian unit for 14.46 billion rupees ($159 million) to a con | [Link](https://longbridge.com/en/news/276407932.md) |
| Deals of the day-Mergers and acquisitions | On February 20, several significant mergers and acquisitions were reported. Novartis plans to sell its 70.68% stake in i | [Link](https://longbridge.com/en/news/276433904.md) |
| A Look Into Novartis Inc's Price Over Earnings | Novartis Inc. (NYSE:NVS) stock is currently trading at $166.81, reflecting a 1.80% increase. Over the past month, the st | [Link](https://longbridge.com/en/news/276149996.md) |
| Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity | Enanta Pharmaceuticals received a Buy rating from analyst Brandon Folkes of H.C. Wainwright, with a price target of $20. | [Link](https://longbridge.com/en/news/276474081.md) |
| CSPC Pharmaceutical obtains FDA approval for SYH2082 clinical trial | CSPC Pharmaceutical obtains FDA approval for SYH2082 clinical trial | [Link](https://longbridge.com/en/news/276034485.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.